@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix prov: .
@prefix pav: .
@prefix orcid: .
@prefix codebase: .
@prefix version: .
@prefix instance: .
@prefix process: .
@prefix np: .
@prefix rdfs: .
@prefix xsd: .
@prefix has-source: .
@prefix d: .
@prefix dv: .
@prefix dr: .
@prefix npx: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
d:DB01111 dv:ddi-interactor-in dr:DB01111_DB01172 .
d:DB01172 dv:ddi-interactor-in dr:DB01111_DB01172 .
dr:DB01111_DB01172 dcterms:identifier "drugbank_resource:DB01111_DB01172";
dcterms:title "DDI between Colistimethate and Kanamycin - Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely."@en;
a dv:Drug-Drug-Interaction;
rdfs:label "DDI between Colistimethate and Kanamycin - Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. [drugbank_resource:DB01111_DB01172]"@en .
}
sub:provenance {
sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
sub:signature.MCwCFBM8lgg1D1jI npx:hasPublicKey "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";
npx:hasSignature "MCwCFBM8lgg1D1jIP/C2+A7OXP9Hf+VXAhQMfh0KXmb3tRhduIGj+KLL0gJzTA==";
npx:signedBy instance: .
this: dcterms:created "2018-03-30T11:12:46.427+02:00"^^xsd:dateTime;
dcterms:license ;
npx:hasSignatureElement sub:signature.MCwCFBM8lgg1D1jI;
prov:wasGeneratedBy process: .
instance: prov:specializationOf codebase:;
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
prov:used version:;
prov:wasAssociatedWith instance:;
prov:wasStartedBy orcid:0000-0002-1267-0234 .
version: dcterms:isVersionOf codebase:;
pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}